Atazanavir Sulfate CAS 229975-97-7 Munditia ≥99.0% API Factory Anti-HIV HIV-1 Protease Inhibitor

Description:

Chemical Name: Atazanavir Sulfate

CAS: 229975-97-7

Aspectus: Alba vel Off-White pulveris

Puritas: ≥99.0%

HIV-1 Protease Inhibitor

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Copia cum summa puritate et stabulo Quality
Chemical Name: Atazanavir Sulfate
CAS: 229975-97-7
HIV-1 Protease Inhibitor
API High Quality, Commercial Production

Chemical Properties:

Nomen chemicum	Atazanavir Sulfate
Synonyma	BMS-232632 Sulfate
CAS Number	229975-97-7
CATTUS Number	RF-API71
Stock Status	In Stock, Productio Ascendite usque ad Centum chiliogrammata
Formulae hypotheticae	C38H52N6O7.H2SO4
M. Pondus	802.93
Liquescens punctum	195.0~ 198.0℃
Solubilitas	Insolubilis in aqua, solubilis in DMSO
Long-Term PRAECLUSIO	Copia Diu terminus in -20℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba vel Off-White pulveris
Sulfate	12.0~12.5%
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.10%
Metalla gravis	≤20ppm
una immunditia	≤0.30%
Totalis immunditias	≤1.0%
Puritas / Analysis Methodo	≥99.0% (HPLC)
pH	5.0~8.0
Test Standard	Enterprise Standard
Consuetudinem	HIV-1 Protease Inhibitor Anti-HIV

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard Drum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

FAQ:

Applicatio:

Atazanavir Sulfate (Sulfate BMS-232632) (CAS: 229975-97-7) est forma salis sulfatis atazanavir, quae est inhibitor maxime selectivus HIV-1 protease, primus protease inhibitor pro semel cottidiana administratione approbatus est.Atazanavir Sulfate subiecta et inhibitor CYP3A4 est, et inhibitor et inductor P-glycoprotein (P-gp).Atazanavir Sulfate etiam SARS-CoV 3CLpro inhibitor cum IC50 of 3.49 μM est.Atazanavir Sulfate est azapeptida et HIV-protease inhibitor quae in curatione contagionum HIV et AIDS cum aliis agentibus Anti-HIV coniunctione adhibita est, a Bristol-Myers Squibb (BMS), sub licentia terrarum Novartis, evoluta est et immissa; ad curationem HIV infectionis.Atazanavir in Reyataz™ mense Iulio 2003. Antiviralem in US est deductam.Atazanavir plerumque potentiorem quam quinque probati HIV-1 protease inhibitores esse ostendit.Atazanavir selective vetat processum speciale virialis Gag et Gag-Pol polyprotein in HIV-1 cellulis infectis ligando ad locum activum HIV-1 protease, ita formationem virionum maturarum praeveniens.Atazanavir non agit contra HIV-2.